Milrinone is also known by its brand name, Primacor [1].
What is Milrinone used for?
Milrinone is used to treat short-term heart failure [2]. It is administered intravenously to patients who are unable to improve with other treatments [2].
How does Milrinone work?
Milrinone is a phosphodiesterase-3 (PDE3) inhibitor [3]. It works by increasing the levels of cyclic adenosine monophosphate (cAMP) in heart muscle cells [3]. This leads to an increase in the contractility of the heart muscle (positive inotropy) and vasodilation, which relaxes blood vessels [3]. These actions help the heart pump blood more effectively and reduce the workload on the heart [3].
What are the potential side effects of Milrinone?
Common side effects of Milrinone include headache, nausea, vomiting, and diarrhea [2]. More serious side effects can occur, such as irregular heart rhythms (arrhythmias), a drop in blood pressure (hypotension), and chest pain [2].
When does the patent for Primacor (Milrinone) expire?
Patent information for specific drugs can be complex and may involve multiple patents covering different aspects of the drug, such as composition of matter, manufacturing processes, and methods of use. Information on specific patent expiry dates for Primacor is not readily available in this context but can be accessed through specialized databases. For detailed patent information, resources like DrugPatentWatch.com can be consulted [4].
Are there generic versions of Milrinone available?
Yes, generic versions of milrinone are available [5]. The availability of generic alternatives can impact the market and pricing of the drug.
How is Milrinone administered?
Milrinone is administered intravenously [2]. It is typically given in a hospital setting under medical supervision due to the need for close monitoring of heart function and blood pressure [2].
What are the alternatives to Milrinone for heart failure?
Treatment for heart failure is individualized and may include various medications such as ACE inhibitors, beta-blockers, diuretics, and other inotropic agents [6]. The choice of treatment depends on the specific type and severity of heart failure, as well as the patient's overall health status [6].
What clinical data supports the use of Milrinone?
Clinical trials have demonstrated that milrinone can improve hemodynamic function in patients with severe heart failure [3]. Studies have shown increases in cardiac output and reductions in pulmonary capillary wedge pressure [3]. However, long-term use has been associated with increased mortality in some patient populations, leading to its primary use in short-term treatment [3].
What do patients need to know about Milrinone treatment?
Patients receiving milrinone should be closely monitored by healthcare professionals for potential side effects, including changes in heart rate, blood pressure, and fluid balance [2]. They should report any unusual symptoms to their medical team immediately [2].
Who manufactures Milrinone?
The original brand name for milrinone was Primacor, manufactured by Sanofi-Aventis [1]. Generic versions are produced by various pharmaceutical companies.
What is the typical dosage of Milrinone?
Dosage of milrinone is highly individualized and depends on the patient's response and clinical condition. It is administered under strict medical supervision by healthcare professionals [2].
Sources
[1] Milrinone - Wikipedia. https://en.wikipedia.org/wiki/Milrinone
[2] Milrinone Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a682071.html
[3] Milrinone: Indications, adverse effects, and contraindications - UpToDate. https://www.uptodate.com/contents/milrinone-indications-adverse-effects-and-contraindications
[4] DrugPatentWatch.com. https://www.drugpatentwatch.com/
[5] Milrinone Generic - GoodRx. https://www.goodrx.com/milrinone
[6] Heart failure - Diagnosis and treatment - Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-failure/diagnosis-treatment/drc-20354453